PASADENA, Texas--(BUSINESS WIRE)--The Huntington Study Group has launched a Phase III clinical trial, funded by the National Institute of Neurological Disorders and Stroke (part of the National Institutes of Health [NIH]), to determine the effect of the maximum effective dosage of Coenzyme Q10 on cognitive function in individuals with Huntington’s Disease (HD). They will also examine the long-term safety of CoQ10. Currently, there is no known cure or effective drug therapy for HD, a genetic, progressive brain disorder that causes uncontrolled movements, cognitive difficulties and emotional disturbances. According to the Huntington’s Disease Society of America, more than a quarter of a million Americans have HD or are “at risk” of inheriting the disease from an affected parent.
